Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business and Basis of Presentation - Business Disposals - Discontinuing Operations (Details)

v3.19.3
Organization, Description of Business and Basis of Presentation - Business Disposals - Discontinuing Operations (Details) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 24, 2019
Jul. 15, 2019
Jul. 05, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Jul. 17, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Excess Consideration Note       $ 6,795,000   $ 6,795,000   $ 0  
Interest paid       38,000 $ 383,000 2,211,000 $ 1,195,000    
Advance from NovellusDx, Ltd.           0 1,500,000    
Earn-Out from siParadigm, current portion       693,000   693,000   0  
Earn-Out from siParadigm, less current portion       594,000   594,000   0  
Advance from siParadigm, less current portion       505,000   505,000   0  
BioPharma Disposal                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Gross consideration   $ 23,500,000              
Closing adjustments   1,978,240              
Promissory note receivable   7,692,300              
Cash received from transaction   $ 2,258,450              
Excess Consideration Note       6,795,000 0 6,795,000 0    
Subsequent Events                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Excess consideration note matured amount $ 6,024,489                
Subsequent Events | BioPharma Disposal                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Gross consideration $ 153,000                
Interest rate 6.00%                
Interest paid $ 23,674                
Net worth adjustment 775,000                
Security for indemnification obligations $ 735,000                
Convertible Note                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Term note, principal balance                 $ 2,625,000
PFG | Secured Debt                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Term note, principal balance       6,000,000   6,000,000      
siParadigm                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Advance, current       469,000   469,000   $ 0  
Clinical Agreement                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Period of service     12 months            
Cash consideration received, total     $ 758,000            
Cash consideration received for equipment     45,000            
Advance from NovellusDx, Ltd.     1,000,000            
Supplier invoices paid directly to related party     177,000            
Transaction costs     $ 110,000            
Term of contract     24 months            
Non-compete term     3 years            
Transition Services Agreement | Maximum | BioPharma Disposal                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Period of service   6 months              
Discontinuing Operations | Convertible Note                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Interest expense, debt       $ 22,000 $ 105,000 $ 1,464,000 $ 105,000